31239321Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison MLClinical cancer research : an official journal of the American Association for Cancer ResearchAntineoplastic Agents, Immunological; Head and Neck Neoplasms; Neoplasm Recurrence, Local; Squamous Cell Carcinoma of Head and NeckAdult; Aged; Aged, 80 and over; Cetuximab; ErbB Receptors; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Nivolumab; Programmed Cell Death 1 Receptor; Survival RateNivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res. 2019 09 01; 25(17):5221-5230.Clin Cancer Res2019-06-25T00:00:002019Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461294Aged, 80 and overD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD007167Procedures1836270.665954ImmunotherapyAuthorship 13048370.1797620.1797621authors10.2514has subject areaD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD006258Disorders15210510.576772Head and Neck NeoplasmsD006801Living Beings2262862810.130052HumansD009362Disorders26910560.715963Neoplasm MetastasisD009364Disorders33613050.61985Neoplasm Recurrence, LocalD015996Concepts & Ideas45518560.724887Survival RateD061026Chemicals & Drugs911590.882236Programmed Cell Death 1 ReceptorD000068818471130.945048CetuximabD000074322851850.820832Antineoplastic Agents, ImmunologicalD066246Chemicals & Drugs1494850.779528ErbB ReceptorsMedicineUniversity of ChicagoEverett E.VokesEverett E. Vokes41.78927490000000-87.601250000000001920Vokes, Everett E.Professortrue1ProfessorProfessor